Elacestrant 345mg tablets
NHS hospitals in England used £25,418,944 of indicative cost of Elacestrant 345mg tablets in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 307.1% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Elacestrant 345mg tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Elacestrant 345mg tablets most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| The Clatterbridge Cancer Centre Nhs Ft | £1,093,660 |
| The Royal Marsden Nhs Foundation Trust | £1,061,154 |
| East And North Hertfordshire Nhs Trust | £822,080 |
| Maidstone And Tunbridge Wells Nhs Trust | £772,797 |
| Royal Surrey County Hosp Nhs Found Trust | £735,835 |
| The Christie Nhs Foundation Trust | £722,466 |
| Nottingham University Hospitals Trust | £699,135 |
| Sheffield Teaching Hospitals Nhs Trust | £689,960 |
| Univ Hpl B/Ham Nhs Foundation Trust | £682,620 |
| Royal Cornwall Hospitals Nhs Trust | £638,056 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.